Hexagon Bio

9:15 AM - 9:30 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Hexagon Bio is turning the world’s DNA data into new medicines. Our proprietary platform combines a large-scale sequencing program, data science and synthetic biology to discover target-specific therapies. We are focused on oncology and anti-infectives, especially cancer metabolism, synthetic lethal vulnerabilities, and “undruggables” such as RAS and protein-protein interactions. We have 8 preclinical programs in oncology and one preclinical antifungal program, which we are pursuing towards clinical trials.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
1st: preclinical small molecule in cancer metabolism, oxidative phosphorylation. 2nd: antifungal
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4